Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205330 | 0.91 | MRGPRX4 (0.32) | MRGPRX4ADORA3DUSP3ALDH1A1HTT | |
| SCHEMBL203025 | 0.91 | MRGPRX4 (0.32) | MRGPRX4ADORA3DUSP3 | |
| SCHEMBL3602924 | 0.89 | ADORA3 (0.39) | MRGPRX4ADORA3ALDH1A1HTTNPC1 | |
| SCHEMBL204090 | 0.88 | MRGPRX4 (0.34) | MRGPRX4ADORA3ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL203080 | 0.87 | ADORA3 (0.32) | MRGPRX4ADORA3 | |
| SCHEMBL203001 | 0.86 | MRGPRX4 (0.34) | MRGPRX4ADORA3DUSP3ALDH1A1HTT | |
| SCHEMBL204233 | 0.85 | MRGPRX4 (0.32) | MRGPRX4ADORA3ALDH1A1 | |
| SCHEMBL202965 | 0.84 | ADORA3 (0.39) | MRGPRX4ADORA3 | |
| SCHEMBL203397 | 0.84 | MRGPRX4 (0.31) | MRGPRX4ADORA3 | |
| SCHEMBL203660 | 0.84 | NR1H2 (0.32) | MRGPRX4ADORA3ALDH1A1HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428148-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3498696-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARASITICIDAL COMPOUNDS | Merial, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3428148-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3050874-B1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL INC (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3088384-B1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2010056999-A9 | ENANTIOMERICALLY ENRICHED ARYLOAZOL- 2 -YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | MERIAL LIMITED (US) | 2018-06-07 | — | — | WO | disclosed |
| EP-3088384-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | Merial, Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-2155699-B9 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-3050874-A1 | ENANTIOMERIALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO PARACITICIDAL COMPOUNDS | Merial, Inc. (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2639228-B1 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8314146-B2 | Thioamide compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-11-20 | — | — | US | disclosed |
| US-8283475-B2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2358687-B1 | Thioamide compounds, method of making and method of using thereof | MERIAL LTD (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8088801-B2 | Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110190231-A1 | THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2011-08-04 | — | — | US | disclosed |
| US-7964621-B2 | Thioamide compounds, method of making and method of using thereof | MERIAL LIMITED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20100130565-A1 | THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2010-05-27 | — | — | US | disclosed |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2010-05-20 | — | — | US | disclosed |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | MRGPRX4 1520/4885ADORA3 354/4885DUSP3 3970/4885 |
| US-20080312272-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | MRGPRX4 1520/4885ADORA3 354/4885DUSP3 3970/4885 |
| US-20100130565-A1 | THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | TST, TMT1A, TPMT | MRGPRX4 945/4885ADORA3 367/4885DUSP3 4491/4885 |
| US-20100125089-A1 | ENANTIOMERICALLY ENRICHED ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4B1, NPY4R, CYP4X1 | MRGPRX4 1222/4885ADORA3 115/4885DUSP3 3063/4885 |
| US-20110190231-A1 | THIOAMIDE COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | TST, TMT1A, TPMT | MRGPRX4 945/4885ADORA3 367/4885DUSP3 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.